Reduced levels of 5-α reductase 2 in adult prostate tissue and implications for BPH therapy

Prostate

Volumn 71, Issue 12, 2011, Pages 1317-1324

  Niu, Yinong ^a,b   Ge, Rongbin ^a   Hu, Libing ^a   Diaz, Christian ^a   Wang, Zongwei ^a   Wu, Chin Lee ^a   Olumi, Aria F ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

5 reductase; prostate; resistance to therapy

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; FINASTERIDE; PARAFFIN; STEROID 5ALPHA REDUCTASE 2;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOREACTIVITY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE EPITHELIUM; PROSTATE HYPERTROPHY; PROTEIN METHYLATION;

AGED; CELL LINE, TRANSFORMED; CHOLESTENONE 5 ALPHA-REDUCTASE; CPG ISLANDS; DNA METHYLATION; DOWN-REGULATION; EPITHELIAL CELLS; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; ISOENZYMES; MALE; MIDDLE AGED; PROMOTER REGIONS, GENETIC; PROSTATE; PROSTATIC HYPERPLASIA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 79960708988     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21348     Document Type: Article

References (35)

1. Roehrborn CG,: Pathology of benign prostatic hyperplasia. Int J Impot Res 2008; 20 (Suppl 3): S8-11.
2. Shapiro E, Becich MJ, Hartanto V, Lepor H,: The relative proportion of stromal and epithelial hyperplasia is related to the development of symptomatic benign prostate hyperplasia. J Urol 1992; 147 (5): 1293-1297.
3. Cunha GR, Donjacour AA, Cooke PS, Mee S, Bigsby RM, Higgins SJ, Sugimura Y,: The endocrinology and developmental biology of the prostate. Endocr Rev 1987; 8: 338-363.
4. Labrecque S, Matlashewski GJ,: Viability of wild type p53-containing and p53-deficient tumor cells. Oncogene 1995; 11 (2): 387-392.
5. Li W, Wu CL, Febbo PG, Olumi AF,: Stromally expressed c-Jun regulates proliferation of prostate epithelial cells. Am J Pathol 2007; 171 (4): 1189-1198. (Pubitemid 47582893)
6. San Francisco IF, DeWolf WC, Peehl DM, Olumi AF,: Expression of transforming growth factor-beta 1 and growth in soft agar differentiate prostate carcinoma-associated fibroblasts from normal prostate fibroblasts. Int J Cancer 2004; 112 (2): 213-218. (Pubitemid 39244360)
7. Cunha GR,: Role of mesenchymal-epithelial interactions in normal and abnormal development of the mammary gland and prostate. Cancer 1994; 74 (3 Suppl): 1030-1044. (Pubitemid 24231999)
8. Bullock TL, Andriole GL, Jr:, Emerging drug therapies for benign prostatic hyperplasia. Expert Opin Emerg drugs 2006; 11 (1): 111-123.
9. McConnell JD, Bruskewitz R, Walsh P, et al.: The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. N Engl J Med 1998; 338 (9): 557-563. (Pubitemid 28114643)
10. Andriole GL, Guess HA, Epstein JI, et al.: Treatment with finasteride preserves usefulness of prostate-specific antigen in the detection of prostate cancer: Results of a randomized, double-blind, placebo-controlled clinical trial. PLESS Study Group. Proscar Long-Term Efficacy and Safety Study. Urology 1998; 52 (2): 195-201, discussion 2.
11. Babaian RJ, Miyashita H, Evans RB, Ramirez EI,: The distribution of prostate specific antigen in men without clinical or pathological evidence of prostate cancer: Relationship to gland. J Urol 1992; 147 (3 Pt 2): 837-840.
12. Bruskewitz R, Girman CJ, Fowler J, et al.: Effect of finasteride on bother and other health-related quality of life aspects associated with benign prostatic hyperplasia. PLESS Study Group. Proscar Long-Term Efficacy and Safety Study. Urology 1999; 54 (4): 670-678. (Pubitemid 29449428)
13. Yang XJ, Lecksell K, Short K, et al.: Does long-term finasteride therapy affect the histologic features of benign prostatic tissue and prostate cancer on needle biopsy? PLESS Study Group. Proscar Long-Term Efficacy and Safety Study. Urology 1999; 53 (4): 696-700. (Pubitemid 29163032)
14. Jones PA, Baylin SB,: The epigenomics of cancer. Cell 2007; 128 (4): 683-692. (Pubitemid 46273572)
15. Zhang X, Jin TG, Yang H, DeWolf WC, Khosravi-Far R, Olumi AF,: Persistent c-FLIP(L) expression is necessary and sufficient to maintain resistance to tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in prostate cancer. Cancer Res 2004; 64 (19): 7086-7091. (Pubitemid 39331021)
16. Bruchovsky N, Sadar MD, Akakura K, Goldenberg SL, Matsuoka K, Rennie PS,: Characterization of 5alpha-reductase gene expression in stroma and epithelium of human prostate. J Steroid Biochem Mol Biol 1996; 59 (5-6): 397-404. (Pubitemid 27037906)
17. Thomas LN, Douglas RC, Lazier CB, Too CK, Rittmaster RS, Tindall DJ,: Type 1 and type 2 5alpha-reductase expression in the development and progression of prostate cancer. Eur Urol 2008; 53 (2): 244-252. (Pubitemid 350296595)
18. Walsh PC, Madden JD, Harrod MJ, Goldstein JL, MacDonald PC, Wilson JD,: Familial incomplete male pseudohermaphroditism, type 2. Decreased dihydrotestosterone formation in pseudovaginal perineoscrotal hypospadias. N Engl J Med 1974; 291 (18): 944-949.
19. Imperato-McGinley J, Guerrero L, Gautier T, Peterson RE,: Steroid 5alpha-reductase deficiency in man: An inherited form of male pseudohermaphroditism. Science 1974; 186 (4170): 1213-1215.
20. Calvanese V, Lara E, Kahn A, Fraga MF,: The role of epigenetics in aging and age-related diseases. Ageing Res Rev 2009; 8 (4): 268-276.
21. Esteller M,: Epigenetics in cancer. N Engl J Med 2008; 358 (11): 1148-1159.
22. Issa JP, Ottaviano YL, Celano P, Hamilton SR, Davidson NE, Baylin SB,: Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon. Nat Genet 1994; 7 (4): 536-540. (Pubitemid 24308343)
23. Ahuja N, Li Q, Mohan AL, Baylin SB, Issa JP,: Aging and DNA methylation in colorectal mucosa and cancer. Cancer Res 1998; 58 (23): 5489-5494. (Pubitemid 28551135)
24. Issa JP, Vertino PM, Boehm CD, Newsham IF, Baylin SB,: Switch from monoallelic to biallelic human IGF2 promoter methylation during aging and carcinogenesis. Proc Natl Acad Sci USA 1996; 93 (21): 11757-11762. (Pubitemid 26347196)
25. Issa JP,: Age-related epigenetic changes and the immune system. Clin Immunol (Orlando, Fla) 2003; 109 (1): 103-108.
26. Ronn T, Poulsen P, Hansson O, et al.: Age influences DNA methylation and gene expression of COX7A1 in human skeletal muscle. Diabetologia 2008; 51 (7): 1159-1168.
27. McNeal JE,: Origin and evolution of benign prostatic enlargement. Invest Urol 1978; 15 (4): 340-345. (Pubitemid 8282023)
28. Shapiro E, Hartanto V, Lepor H,: Quantifying the smooth muscle content of the prostate using double-immunoenzymatic staining and color assisted image analysis. J Urol 1992; 147 (4): 1167-1170.
29. Thompson IM, Goodman PJ, Tangen CM, et al.: The Influence of Finasteride on the development of prostate cancer. N Engl J Med 2003. 349 (3): 215-224. (Pubitemid 36859473)
30. Thompson IM, Chi C, Ankerst DP, et al.: Effect of finasteride on the sensitivity of PSA for detecting prostate cancer. J Natl Cancer Inst 2006; 98 (16): 1128-1133. (Pubitemid 44288787)
31. Thompson IM, Pauler Ankerst D, Chi C, et al.: Prediction of prostate cancer for patients receiving finasteride: Results from the Prostate Cancer Prevention Trial. J Clin Oncol 2007; 25 (21): 3076-3081. (Pubitemid 47218054)
32. Lucia MS, Epstein JI, Goodman PJ, et al.: Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. J Natl Cancer Inst 2007; 99 (18): 1375-1383. (Pubitemid 351767184)
33. Lucia MS, Darke AK, Goodman PJ, et al.: Pathologic characteristics of cancers detected in the Prostate Cancer Prevention Trial: Implications for prostate cancer detection and chemoprevention. Cancer Prev Res (Phila) 2008; 1 (3): 167-173.
34. Redman MW, Tangen CM, Goodman PJ, Lucia MS, Coltman CAJ, Thompson IM,: Finasteride does not increase the risk of high-grade prostate cancer: A bias-adjusted modeling approach. Cancer Prev Res (Phila) 2008; 1 (3): 174-181.
35. Andriole GL, Bostwick DG, Brawley OW, et al.: Effect of dutasteride on the risk of prostate cancer. N Engl J Med 362 (13): 1192-1202.